Outcome and Life Expectancy Associated with Novel Subgroups of Atrial Fibrillation: a Data-Driven Cluster Analysis
Yuefeng Yu,Jiang Li,Ying Sun,Bowei Yu,Xiao Tan,Bin Wang,Yingli Lu,Ningjian Wang
DOI: https://doi.org/10.1101/2023.10.07.23296702
IF: 39.3
2024-01-01
European Heart Journal
Abstract:Aim This study aimed to develop a refined classification of atrial fibrillation (AF) according to comprehensive risk factors to identify patients at high-risk for poor prognosis and their life expectancy. Method A total of 7,391 participants aged 40-69 with AF at baseline, from UK Biobank, were classified into five clusters, based on seven clustering variables including age and six risk factor categories (metabolic disease, respiratory disease, cardiovascular disease, renal/immune-mediated disease, mental health disease, acute illness). Difference in the risk of death and major complications, as well as reductions in life expectancy, among clusters were estimated. Replication was done in 2,399 participants with newly diagnosed AF within two years after baseline. Results Five distinct AF clusters were identified: acute illness-related, mental health-related, cardiovascular disease-related, immune-and-renal disease-related, and respiratory-and- metabolic disease-related AF. Patients with respiratory-and-metabolic disease-related AF had the highest risk of death, acute myocardial infarction, heart failure, and cerebral ischemic stroke, while those with acute illness-related AF had the lowest corresponding risk. In addition, compared with individuals with acute illness-related AF, those with respiratory-and- metabolic disease-related and mental health-related AF had the top 2 greatest loss of life expectancy. Furthermore, genetic variants for AF had different effect among the five clusters. Replication analysis confirmed the result stability. Conclusion A novel AF classification was developed, which provided insights into varying life expectancy and risks of death and complications among AF subgroups with distinct characteristics. It offers a practical approach for identifying high-risk patients, which might help to tailor precise interventions for AF management. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was supported by Shanghai Municipal Health Commission (2022XD017), Clinical Research Plan of SHDC (SHDC2020CR4006), National Natural Science Foundation of China (82170870), Shanghai Municipal Human Resources and Social Security Bureau (2020074), Innovative Research Team of High-level Local Universities in Shanghai (SHSMU-ZDCX20212501). The funders played no role in the design or conduction of the study; in the collection, management, analysis, or interpretation of the data; or in the preparation, review, or approval of the article. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee of the UK National Health Service gave ethical approval for this work Ethics committee of the National Research Ethics Service North West gave ethical approval for this work Ethics committee of the National Information Governance Board for Health and Social Care in England and Wales gave ethical approval for this work Ethics committee of the Community Health Index Advisory Group in Scotland gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes The data underlying this article are available in UK Biobank, at https://www.ukbiobank.ac.uk/.